Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase‐4 inhibitors: Real world evidence from the Nordic EMPRISE study
Authors' conclusion
Empagliflozin treatment compared to DPP-4i reduced cardiorenal events and overall mortality, which may explain lower HCRU among empagliflozin users in Sweden.
Study context
- Population
- Adults with T2D newly initiated on empagliflozin or DPP-4i, May 2014 to December 2018, Sweden (EMPRISE EU study)15,785 matched pairs
- Exposure
- Empagliflozin vs DPP-4i
- Outcome
- Cardiovascular outcomes
- Follow-up
- Mean 6.4 (empagliflozin) and 9.7 months (DPP-4i)
Methodological detailsnon-interventional, Swedish national registries, propensity-score matched 1:1 (>180 covariates)
- Non-interventional
- Swedish national registries
- Propensity-score matched 1:1 (>180 covariates)
Main finding
As reported in the abstract
Each group vs DPP-4iEstimate (95% CI)
Empagliflozin
HR (HHF) 0.67(0.49–0.91)
Empagliflozin
HR (ACM) 0.53(0.41–0.68)
Empagliflozin
HR (HHF + ACM) 0.59(0.48–0.73)
Empagliflozin
HR (MI + stroke + ACM) 0.68(0.57–0.81)
Empagliflozin
HR (CVM) 0.46(0.29–0.73)
Empagliflozin
HR (HHF + CVM) 0.61(0.47–0.79)
Empagliflozin
HR (MI + stroke + CVM) 0.79(0.63–0.98)
Observational data: associations, not effects.
Further findings
| Outcome | Estimate | |
|---|---|---|
| Renal outcomesEmpagliflozinvs DPP-4i | HR (ESRD) 0.13 (CI 0.03–0.57) | |
| Renal outcomesEmpagliflozinvs DPP-4i | HR (eGFR decline to <60 ml/min/1.73 m²) 0.83 (CI 0.70–0.99) | |
| Healthcare resource utilizationEmpagliflozinvs DPP-4iRR: rate ratio | HR (first inpatient stay) 0.87 (CI 0.81–0.93) | |
| Healthcare resource utilizationEmpagliflozinvs DPP-4iRR: rate ratio | RR (inpatient visits) 0.85 (CI 0.80–0.89) | |
| Healthcare resource utilizationEmpagliflozinvs DPP-4iRR: rate ratio | RR (outpatient visits) 0.96 (CI 0.94–0.98) | |
| 0.050.21520Ratio (log scale) |
Original publication
Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase‐4 inhibitors: Real world evidence from the Nordic EMPRISE study. Diabetes Obes Metab. Published 10 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →